fwiw, from YMB
Published in Drugs, authors from VA Ann Arbor Healthcare system, "Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice" Feb 5 2019
Full dose betrixaban is superior in efficacy and non-inferior in safety compared to standard-duration enoxaparin.
Extended-duration enoxaparin is superior in efficacy and inferior in safety compared to standard-duration enoxaparin.
Apixaban and rivaroxaban are non-inferior in efficacy and inferior in safety.
Conclusions: "Full-dose betrixaban is currently the only agent for extended-duration thromboprophylaxis to achieve a favorable net clinical benefit. The use of betrixaban in high-risk, acutely ill hospitalized medical patients similar to patients enrolled in the APEX trial can reduce the risk of thromboembolic events without increasing the risk of major bleeding. Patients who may benefit more from betrixaban therapy include those with elevated d-dimer, a history of VTE, hospitalized for ischemic stroke, hospitalized for HF with NT-proBNP ≥ 1975 ng/L, or two or more VTE risk factors."